Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

[Image: see text] Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality us...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagnolini, Greta, Milano, Domenico, Manerba, Marcella, Schipani, Fabrizio, Ortega, Jose Antonio, Gioia, Dario, Falchi, Federico, Balboni, Andrea, Farabegoli, Fulvia, De Franco, Francesca, Robertson, Janet, Pellicciari, Roberto, Pallavicini, Isabella, Peri, Sebastiano, Minucci, Saverio, Girotto, Stefania, Di Stefano, Giuseppina, Roberti, Marinella, Cavalli, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997579/
https://www.ncbi.nlm.nih.gov/pubmed/32037829
http://dx.doi.org/10.1021/acs.jmedchem.9b01526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997579/
https://www.ncbi.nlm.nih.gov/pubmed/32037829
http://dx.doi.org/10.1021/acs.jmedchem.9b01526

Ejemplares similares